Sarepta's Elevidys revenue cratered 73% to $102 million as a boxed warning and three deaths gutted the gene-therapy story

---

There is a moment in the life of a biotech where the story stops being about science and starts being about survival, and you can usually date it precisely. For Sarepta Therapeutics, the moment was not a single press release but a sequence of them — patient deaths attributed to acute liver failure, a boxed warning, a revoked vector designation, clinical holds across the pipeline, a halt of all U.S. Elevidys shipments, and a restructuring that cut more than a third of the company. By the time Sarepta reported first-quarter 2026 results on May 6, 2026, Elevidys net product revenue had fallen to $102.0 million from $375 million in the first quarter of 2025, a decline of roughly 73 percent. The flagship gene therapy — the entire reason the stock once traded near a $14 billion market value — had been reduced, in a single year, to a minority contributor to the company's own product line.

This is a forensic piece about what happens when a "secular growth" story collides with a denominator it cannot control: the eligible patient population. Sarepta's bull case was always demographic and durable — Duchenne muscular dystrophy is a fatal, progressive disease, the gene therapy is a one-time treatment, the addressable pool of boys is finite but real, and Sarepta got there first. None of that was wrong. What the bull case underweighted was that the size of the addressable pool is not fixed by biology alone. It is set, quarter to quarter, by the FDA's tolerance for a drug that has now been linked to deaths. When the regulator narrows the label, the denominator shrinks — and a "secular" franchise reprices overnight as a binary regulatory bet. That repricing has already happened. The question is whether it is finished.

The number that broke the thesis: $375 million to $102 million

Start with the figure the entire story hinges on, because it is unambiguous and it comes straight from the company. In the first quarter of 2026, Sarepta reported total net product revenues of $330.5 million, composed of $102.0 million of Elevidys net product revenue and $228.6 million of PMO net product revenues — the older RNA-based exon-skipping drugs, Exondys 51, Vyondys 53, and Amondys 45. One year earlier, in the first quarter of 2025, Elevidys alone generated roughly $375 million. That is a collapse of about 73 percent in the company's marquee asset, and it inverts the entire narrative arc. Elevidys was supposed to be the growth engine that made the legacy PMO franchise look like a rounding error. Instead, in the most recent quarter, the legacy PMO drugs out-earned the gene therapy more than two to one.

Management's framing of this is a study in optimism under pressure. On the same call, Sarepta told investors that "our commercial portfolio has begun to stabilize" and that Elevidys "is positioned to return to growth." Both statements may even prove true. But notice what the framing does: it converts a 73 percent year-over-year revenue collapse into a setup for a comeback. A forensic reader should hold both ideas at once — the stabilization may be real, and the base it is stabilizing from is roughly a quarter of where it was. Returning to growth off a $102 million quarterly base is a very different proposition from compounding off a $375 million one. The slope can be positive while the altitude has been cut to the floor.

The deaths are the denominator

The reason Elevidys revenue fell is not pricing, not competition, not a soft launch. It is safety, and specifically mortality. Two nonambulatory Duchenne patients treated with Elevidys died, with both deaths attributed to acute liver failure. Separately, a 51-year-old patient in a Phase 1 trial of Sarepta's investigational limb-girdle muscular dystrophy gene therapy, SRP-9004, also died — a death likewise reported as related to acute liver failure. Three deaths, linked by a common mechanism of hepatic toxicity, across a vector platform Sarepta had built its future on.

The regulatory response was not gradual. The FDA added a boxed warning — the agency's most serious — for the risk of acute serious liver injury and acute liver failure to the Elevidys label. It removed eligibility for nonambulatory patients, the more advanced, higher-risk population, entirely. It revoked the platform designation it had previously granted for the AAVrh74 viral vector that underpins multiple Sarepta programs, and it placed clinical holds on trials evaluating SRP-9004 and SRP-9003 (bidridistrogene xeboparvovec), the limb-girdle candidates that shared the same vector. And, after an initial standoff, Sarepta agreed to a voluntary halt of all U.S. Elevidys shipments to address the FDA's questions.

This is the denominator illusion in its most literal, most human form. A gene-therapy total addressable market is a count of eligible patients multiplied by a price. Strip out the nonambulatory cohort, and you have not trimmed the market — you have deleted a tranche of it by regulatory fiat. The "secular" patient pool that justified the multiple was never a fixed biological constant. It was a label, and the label is now narrower and bears a black box.

Shipments resumed — but read the fine print

The bull will respond, correctly, that the story did not end at the pause. The FDA subsequently informed Sarepta that it recommended removing the voluntary hold and resuming shipments of Elevidys for ambulatory individuals with Duchenne, and Sarepta announced it would resume shipping to sites of care for ambulatory patients. That is genuine good news, and the market treated it as such. A company that had effectively zero forward U.S. revenue visibility during the halt regained a commercial pulse.

But a forensic reading insists on the qualifier embedded in every one of those sentences: ambulatory. The resumption applies to the population that can still walk. The nonambulatory cohort — the patients further along in a relentlessly progressive disease, the ones with arguably the most urgent need — remains off-label in the United States, walled off by the same safety signal that drove the deaths. So the "return to growth" management is selling runs entirely off the ambulatory base, into a market that now knows the drug carries a boxed warning for fatal liver injury, and that will be prescribed by clinicians who watched the FDA revoke the vector's platform designation. Demand is not a switch the FDA flipped back on. It is a clinical-confidence problem, and clinical confidence does not return on the same timetable as a shipping authorization.

Quality of earnings: the GAAP profit that isn't what it looks like

Here is where the forensic lens earns its keep, because the headline numbers from the quarter look, at a glance, almost reassuring. Sarepta reported GAAP operating income of $358.4 million and non-GAAP operating income of $397.7 million for the first quarter of 2026. It posted net income of roughly $331 million and earnings per share of $3.16, against a consensus estimate near $0.99. On the surface, that reads like a company minting money even as its lead drug stumbles. It is not.

The tell is the gap between total revenues of $730.8 million and net product revenues of $330.5 million. The difference — roughly $400 million — is not recurring drug sales to patients. A large slice of it reflects collaboration and other revenue, including the economics of the Roche partnership and milestone events. In the first quarter, for instance, Sarepta earned a $40.0 million milestone under the Roche collaboration tied to Chugai's commercial launch of Elevidys in Japan. Milestones are real cash, but they are lumpy, non-recurring, and backward-looking — they reward deals already struck, not a franchise that is currently compounding. A GAAP operating profit built substantially on collaboration revenue and milestones, sitting atop a product line whose growth engine just fell 73 percent, is a profit you should age-weight heavily before you capitalize it. The quarter was profitable. The profitability was not the kind you can extrapolate.

The restructuring is the confession

Companies tell you what they actually believe through capital allocation, not through earnings-call adjectives. Sarepta's restructuring is the most honest document in the entire saga. The company announced a strategic restructuring and pipeline-prioritization plan that cut roughly 500 jobs — about 36 percent of its workforce — and is designed to deliver on the order of $400 million in anticipated annual cost savings. Of that, the workforce reduction is expected to generate roughly $120 million in annual cash cost savings in 2026, with the pipeline reprioritization expected to deliver about $300 million in annual non-personnel savings.

Read past the cost-savings arithmetic to what is being cut. Sarepta is discontinuing or scaling back multiple gene-therapy programs — particularly the limb-girdle muscular dystrophy candidates that rode the now-discredited AAVrh74 vector — and refocusing on a small interfering RNA (siRNA) platform. In other words, the company that defined itself as a gene-therapy pioneer is, under regulatory and financial duress, pivoting away from gene therapy toward an earlier-stage modality. A 36 percent headcount cut is not a fine-tuning. It is a balance-sheet survival move by a company that, with cash and investments of $748.3 million as of March 31, 2026 and a debt load layered on top, cannot fund the old ambition and the new reality at once. The restructuring does not say "return to growth." It says "preserve the runway and hope the ambulatory franchise holds."

Cyclical-priced-as-secular, in reverse

The cleanest way to frame the SRPT mispricing is a mirror image of the usual short thesis. Ordinarily the forensic critique is that a cyclical business gets valued as a secular grower. Here, the market did the opposite and is now correcting it violently: it valued a regulatory-contingent franchise as a secular one, and is repricing it as the contingency it always was.

A one-time gene therapy with a boxed warning is not an annuity. Its revenue is a function of three things the company does not control: the regulator's continued tolerance of the safety profile, prescribers' willingness to infuse a drug now associated with deaths, and payers' appetite to reimburse a $3.2-million treatment whose label has been narrowed. Any one of those can deteriorate independently. A second wave of hepatic adverse events, a new clinical hold, a payer policy tightening, a competitor's cleaner data — each is a discrete event that can reset the revenue line again. That is the textbook profile of a binary, event-driven security, not a compounder. The stock's behavior — down more than 80 percent over the year, a market value that slid from roughly $3.7 billion in mid-2025 toward about $1.85 billion by June 2026 — is the market belatedly applying the right valuation framework to the wrong-framed asset.

The competitive clock the deaths started

Safety crises do not happen in a vacuum; they hand the field to whoever is next in line. Sarepta's first-mover advantage in Duchenne was its single most valuable asset, and the boxed warning has quietly converted that advantage into a liability — because it gives every competitor a clean differentiator to sell against. REGENXBIO has signaled plans to file for approval of its Duchenne gene therapy, RGX-202, with a different capsid; Solid Biosciences and others are advancing programs; Pfizer's earlier large trial, despite its own historical setbacks, kept the category competitive. None of these is guaranteed to succeed. But each now competes against an incumbent whose label reads "boxed warning: acute liver failure" and whose vector lost its FDA platform designation.

That is the moat-versus-loophole problem in sharp relief. Sarepta's moat was supposed to be the regulatory head start and the manufacturing know-how. What the past year revealed is that the head start was partly a loophole in time — Sarepta got to market first under accelerated pathways, and the safety reckoning that followed is precisely the kind of event that lets fast-followers reframe "first" as "the one with the deaths." The royalty stream from Roche outside the U.S. and the milestone economics provide some insulation, but they do not refill the competitive moat that hepatic toxicity drained.

The legacy franchise is the floor — and it's eroding too

If the gene therapy is the binary, the older PMO drugs are supposed to be the ballast — the $228.6 million of quarterly revenue that keeps the lights on while Elevidys recovers. But this ballast is not pristine either. Exondys 51, Vyondys 53, and Amondys 45 were approved under the accelerated pathway, on a surrogate endpoint (dystrophin expression) whose clinical benefit has long been debated. In April 2026, Sarepta submitted supplemental new drug applications seeking to convert Amondys 45 and Vyondys 53 from accelerated to traditional approval — an effort to firm up the regulatory standing of the very drugs now carrying the company. That filing is a tacit acknowledgment that the legacy floor rests on accelerated approvals that are not, themselves, beyond question in a now-skeptical regulatory environment.

So the "floor" under the binary is itself a set of surrogate-endpoint approvals seeking to be upgraded, sold into the same finite Duchenne population, by a sales force that just shrank by 36 percent. It is a real revenue line, and it is the most stable thing Sarepta owns right now. But it is not growth, and its durability depends on the same FDA whose posture toward Sarepta has turned, by any reading, considerably colder over the past year.

What the bulls genuinely get right

A forensic case that refuses to concede the other side's strongest points is propaganda, so here is where the bull thesis is genuinely, specifically strong — and it is stronger than the stock chart implies.

First, the unmet need is real and the science works. Duchenne muscular dystrophy is fatal and progressive, and Elevidys is the first and only approved gene therapy for it. For the ambulatory boys who can receive it, this is not a lifestyle drug; it is a one-time intervention against a disease that otherwise takes mobility and then life. That clinical reality creates durable demand that no spreadsheet can fully extinguish.

Second, shipments have resumed. The FDA's decision to recommend removing the voluntary hold and allow Elevidys back to ambulatory patients is a material de-risking event. The worst-case scenario priced into the stock during the halt — an indefinite zero on U.S. gene-therapy revenue — did not materialize. The company has a commercial pulse again.

Third, the balance sheet bought time. Cash and investments of $748.3 million as of March 31, 2026, combined with a restructuring targeting roughly $400 million in annual savings, gives Sarepta a credible multi-quarter runway to let the ambulatory franchise re-stabilize. The first quarter was GAAP-profitable, even if the quality is mixed, and management reiterated full-year 2026 net product revenue guidance of $1.2 billion to $1.4 billion — a range that, if achieved, implies the back half of the year recovers meaningfully from the depressed Q1 base.

Fourth, the Roche partnership is a genuine, diversifying asset. Mid-teens royalties on ex-U.S. net sales, plus milestone payments like the $40.0 million Japan-launch milestone, provide a revenue stream that is partly insulated from U.S. regulatory whiplash and that the market arguably under-credits when it values Sarepta purely on the U.S. Elevidys line. None of this makes the bear case wrong. It makes it a bet on the second derivative — on whether the safety signal worsens — rather than a foregone conclusion.

The kicker

Strip away the adjectives and Sarepta is now a single trade expressed as a stock: a wager on whether a gene therapy linked to three deaths and wearing the FDA's blackest warning can rebuild prescriber confidence faster than competitors with cleaner data can take the field. The bull and bear cases do not actually disagree about the facts — Elevidys revenue fell roughly 73 percent to $102.0 million, the workforce was cut 36 percent, shipments resumed but only for ambulatory patients, the cash is real but finite. They disagree about one unknowable: whether the next safety report is silence or another liver. The company calls this "positioned to return to growth." A forensic reader calls it what the option-pricing already knows it to be.

A company whose entire equity value now rides on the absence of the next death is not a growth story that stumbled — it is a binary safety bet wearing the costume of a franchise, and the market has finally started charging it the option premium that costume always deserved.